Global Blood Plasma Fractionators
Global Blood Plasma Fractionators

Blood Plasma Fractionators Comprehensive Study by Type (Membrane Plasma Plasma Fractionator, Non-Membrane Plasma Fractionator), Application (Neurology, Immunology, Hematology, Critical care, Pulmonology, Others), End-User (Hospitals & Clinics, Clinical Research Laboratories, Academic Institutes) Players and Region - Global Market Outlook to 2026

Blood Plasma Fractionators Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jul 2021 Edition 210 Pages 214 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Fractionation is a method of separating a specific amount of a mixture. Furthermore, plasma is the fluid component of blood that is separated to produce albumin and immunoglobulins, among other plasma derivatives. These plasma-derived compounds have therapeutic properties and are used to treat a variety of blood plasma-related illnesses. Coagulation factor VIII, for example, is a plasma product that is used to treat and prevent haemophilia. Additionally, it is used to prevent excessive blood loss during surgical procedures. Immunoglobulins are also used to treat immunological deficits, both primary and secondary.Immunoglobulins produced from plasma are increasingly being employed in a variety of clinical settings, including autoimmune and inflammatory illnesses. Ceruloplasmin, IgA, and Plasmin are among the medicines that the plasma fractionation market has heavily invested in. Furthermore, the market would be boosted by rising investments in innovation and technological breakthroughs in efficient and cost-effective protein fractionation techniques.This growth is primarily driven by The growing use of Immunoglobulins in Various Therapeutic Areas, Rising Geriatric Population and Increase in Number of Plasma Collection Centers Across the Globe.

Globally, a noticeable market trend is evident Rising Prevalence of Bleeding Disorders. Major Players, such as CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), LFB (France), Biotest (Germany), Takeda Pharmaceutical Company (Japan), Bio Products Laboratory (United Kingdom) and Bharat Serums and Vaccines Limited (India) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

April 2020 Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring) and Takeda Pharmaceutical Company Limited to develop a potential plasma-derived therapy for treating COVID-19. and April 2020 Grifols (Spain) launched 3-mL (900-IU) vial for HyperRAB (rabies immune globulin [human]) in the plasma fractionation market.

Market Drivers
  • The growing use of Immunoglobulins in Various Therapeutic Areas
  • Rising Geriatric Population
  • Increase in Number of Plasma Collection Centers Across the Globe

Market Trend
  • Rising Prevalence of Bleeding Disorders

Restraints
  • High Cost of Plasma Derived Products
  • The emergence of Recombinant Alternatives

Opportunities
Increased Risk of Pandemics and Communicable Diseases and Albumin Shows Lucrative Growth Opportunity

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Blood Plasma Fractionators Study Sheds Light on
— The Blood Plasma Fractionators Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Blood Plasma Fractionators industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Blood Plasma Fractionators industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What are the years considered in the Blood Plasma Fractionators Market?
Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026

2. Who are the key players profiled in the Blood Plasma Fractionators Market?
Companies that are profiled in Global Blood Plasma Fractionators Market are CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), LFB (France), Biotest (Germany), Takeda Pharmaceutical Company (Japan), Bio Products Laboratory (United Kingdom) and Bharat Serums and Vaccines Limited (India) etc.

3. What is Blood Plasma Fractionators Market?
Fractionation is a method of separating a specific amount of a mixture. Furthermore, plasma is the fluid component of blood that is separated to produce albumin and immunoglobulins, among other plasma derivatives. These plasma-derived compounds have therapeutic properties and are used to treat a variety of blood plasma-related illnesses. Coagulation factor VIII, for example, is a plasma product that is used to treat and prevent haemophilia. Additionally, it is used to prevent excessive blood loss during surgical procedures. Immunoglobulins are also used to treat immunological deficits, both primary and secondary.Immunoglobulins produced from plasma are increasingly being employed in a variety of clinical settings, including autoimmune and inflammatory illnesses. Ceruloplasmin, IgA, and Plasmin are among the medicines that the plasma fractionation market has heavily invested in. Furthermore, the market would be boosted by rising investments in innovation and technological breakthroughs in efficient and cost-effective protein fractionation techniques.
Report Objectives / Segmentation Covered
By Type
  • Membrane Plasma Plasma Fractionator
  • Non-Membrane Plasma Fractionator
By Application
  • Neurology
  • Immunology
  • Hematology
  • Critical care
  • Pulmonology
  • Others
By End-User
  • Hospitals & Clinics
  • Clinical Research Laboratories
  • Academic Institutes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Spain
    • Rest of Europe
  • MEA
    • Saudi Arabia
    • Turkey
    • Israel
    • United Arab Emirates
    • South Africa
    • Rest of Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The growing use of Immunoglobulins in Various Therapeutic Areas
      • 3.2.2. Rising Geriatric Population
      • 3.2.3. Increase in Number of Plasma Collection Centers Across the Globe
    • 3.3. Market Trends
      • 3.3.1. Rising Prevalence of Bleeding Disorders
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Blood Plasma Fractionators, by Type, Application, End-User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Blood Plasma Fractionators (Value)
      • 5.2.1. Global Blood Plasma Fractionators by: Type (Value)
        • 5.2.1.1. Membrane Plasma Plasma Fractionator
        • 5.2.1.2. Non-Membrane Plasma Fractionator
      • 5.2.2. Global Blood Plasma Fractionators by: Application (Value)
        • 5.2.2.1. Neurology
        • 5.2.2.2. Immunology
        • 5.2.2.3. Hematology
        • 5.2.2.4. Critical care
        • 5.2.2.5. Pulmonology
        • 5.2.2.6. Others
      • 5.2.3. Global Blood Plasma Fractionators by: End-User (Value)
        • 5.2.3.1. Hospitals & Clinics
        • 5.2.3.2. Clinical Research Laboratories
        • 5.2.3.3. Academic Institutes
      • 5.2.4. Global Blood Plasma Fractionators Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Singapore
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Spain
          • 5.2.4.3.7. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Saudi Arabia
          • 5.2.4.4.2. Turkey
          • 5.2.4.4.3. Israel
          • 5.2.4.4.4. United Arab Emirates
          • 5.2.4.4.5. South Africa
          • 5.2.4.4.6. Rest of Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Blood Plasma Fractionators: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. CSL (Australia)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Grifols (Spain)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Shire (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Octapharma (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Kedrion (Italy)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. LFB (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biotest (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Takeda Pharmaceutical Company (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bio Products Laboratory (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bharat Serums and Vaccines Limited (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Blood Plasma Fractionators Sale, by Type, Application, End-User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Blood Plasma Fractionators (Value)
      • 7.2.1. Global Blood Plasma Fractionators by: Type (Value)
        • 7.2.1.1. Membrane Plasma Plasma Fractionator
        • 7.2.1.2. Non-Membrane Plasma Fractionator
      • 7.2.2. Global Blood Plasma Fractionators by: Application (Value)
        • 7.2.2.1. Neurology
        • 7.2.2.2. Immunology
        • 7.2.2.3. Hematology
        • 7.2.2.4. Critical care
        • 7.2.2.5. Pulmonology
        • 7.2.2.6. Others
      • 7.2.3. Global Blood Plasma Fractionators by: End-User (Value)
        • 7.2.3.1. Hospitals & Clinics
        • 7.2.3.2. Clinical Research Laboratories
        • 7.2.3.3. Academic Institutes
      • 7.2.4. Global Blood Plasma Fractionators Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Singapore
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Spain
          • 7.2.4.3.7. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Saudi Arabia
          • 7.2.4.4.2. Turkey
          • 7.2.4.4.3. Israel
          • 7.2.4.4.4. United Arab Emirates
          • 7.2.4.4.5. South Africa
          • 7.2.4.4.6. Rest of Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Blood Plasma Fractionators: by Type(USD Million)
  • Table 2. Blood Plasma Fractionators Membrane Plasma Plasma Fractionator , by Region USD Million (2015-2020)
  • Table 3. Blood Plasma Fractionators Non-Membrane Plasma Fractionator , by Region USD Million (2015-2020)
  • Table 4. Blood Plasma Fractionators: by Application(USD Million)
  • Table 5. Blood Plasma Fractionators Neurology , by Region USD Million (2015-2020)
  • Table 6. Blood Plasma Fractionators Immunology , by Region USD Million (2015-2020)
  • Table 7. Blood Plasma Fractionators Hematology , by Region USD Million (2015-2020)
  • Table 8. Blood Plasma Fractionators Critical care , by Region USD Million (2015-2020)
  • Table 9. Blood Plasma Fractionators Pulmonology , by Region USD Million (2015-2020)
  • Table 10. Blood Plasma Fractionators Others , by Region USD Million (2015-2020)
  • Table 11. Blood Plasma Fractionators: by End-User(USD Million)
  • Table 12. Blood Plasma Fractionators Hospitals & Clinics , by Region USD Million (2015-2020)
  • Table 13. Blood Plasma Fractionators Clinical Research Laboratories , by Region USD Million (2015-2020)
  • Table 14. Blood Plasma Fractionators Academic Institutes , by Region USD Million (2015-2020)
  • Table 15. South America Blood Plasma Fractionators, by Country USD Million (2015-2020)
  • Table 16. South America Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 17. South America Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 18. South America Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 19. Brazil Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 20. Brazil Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 21. Brazil Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 22. Argentina Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 23. Argentina Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 24. Argentina Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 25. Rest of South America Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 26. Rest of South America Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 27. Rest of South America Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 28. Asia Pacific Blood Plasma Fractionators, by Country USD Million (2015-2020)
  • Table 29. Asia Pacific Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 30. Asia Pacific Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 31. Asia Pacific Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 32. China Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 33. China Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 34. China Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 35. Japan Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 36. Japan Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 37. Japan Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 38. India Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 39. India Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 40. India Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 41. South Korea Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 42. South Korea Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 43. South Korea Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 44. Singapore Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 45. Singapore Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 46. Singapore Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 47. Australia Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 48. Australia Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 49. Australia Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 53. Europe Blood Plasma Fractionators, by Country USD Million (2015-2020)
  • Table 54. Europe Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 55. Europe Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 56. Europe Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 57. Germany Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 58. Germany Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 59. Germany Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 60. France Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 61. France Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 62. France Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 63. Italy Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 64. Italy Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 65. Italy Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 66. United Kingdom Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 67. United Kingdom Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 68. United Kingdom Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 69. Netherlands Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 70. Netherlands Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 71. Netherlands Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 72. Spain Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 73. Spain Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 74. Spain Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 75. Rest of Europe Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 76. Rest of Europe Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 77. Rest of Europe Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 78. MEA Blood Plasma Fractionators, by Country USD Million (2015-2020)
  • Table 79. MEA Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 80. MEA Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 81. MEA Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 82. Saudi Arabia Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 83. Saudi Arabia Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 84. Saudi Arabia Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 85. Turkey Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 86. Turkey Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 87. Turkey Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 88. Israel Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 89. Israel Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 90. Israel Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 91. United Arab Emirates Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 92. United Arab Emirates Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 93. United Arab Emirates Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 94. South Africa Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 95. South Africa Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 96. South Africa Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 97. Rest of Africa Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 98. Rest of Africa Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 99. Rest of Africa Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 100. North America Blood Plasma Fractionators, by Country USD Million (2015-2020)
  • Table 101. North America Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 102. North America Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 103. North America Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 104. United States Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 105. United States Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 106. United States Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 107. Canada Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 108. Canada Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 109. Canada Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 110. Mexico Blood Plasma Fractionators, by Type USD Million (2015-2020)
  • Table 111. Mexico Blood Plasma Fractionators, by Application USD Million (2015-2020)
  • Table 112. Mexico Blood Plasma Fractionators, by End-User USD Million (2015-2020)
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Company Basic Information, Sales Area and Its Competitors
  • Table 119. Company Basic Information, Sales Area and Its Competitors
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Blood Plasma Fractionators: by Type(USD Million)
  • Table 124. Blood Plasma Fractionators Membrane Plasma Plasma Fractionator , by Region USD Million (2021-2026)
  • Table 125. Blood Plasma Fractionators Non-Membrane Plasma Fractionator , by Region USD Million (2021-2026)
  • Table 126. Blood Plasma Fractionators: by Application(USD Million)
  • Table 127. Blood Plasma Fractionators Neurology , by Region USD Million (2021-2026)
  • Table 128. Blood Plasma Fractionators Immunology , by Region USD Million (2021-2026)
  • Table 129. Blood Plasma Fractionators Hematology , by Region USD Million (2021-2026)
  • Table 130. Blood Plasma Fractionators Critical care , by Region USD Million (2021-2026)
  • Table 131. Blood Plasma Fractionators Pulmonology , by Region USD Million (2021-2026)
  • Table 132. Blood Plasma Fractionators Others , by Region USD Million (2021-2026)
  • Table 133. Blood Plasma Fractionators: by End-User(USD Million)
  • Table 134. Blood Plasma Fractionators Hospitals & Clinics , by Region USD Million (2021-2026)
  • Table 135. Blood Plasma Fractionators Clinical Research Laboratories , by Region USD Million (2021-2026)
  • Table 136. Blood Plasma Fractionators Academic Institutes , by Region USD Million (2021-2026)
  • Table 137. South America Blood Plasma Fractionators, by Country USD Million (2021-2026)
  • Table 138. South America Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 139. South America Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 140. South America Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 141. Brazil Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 142. Brazil Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 143. Brazil Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 144. Argentina Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 145. Argentina Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 146. Argentina Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 147. Rest of South America Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 148. Rest of South America Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 149. Rest of South America Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 150. Asia Pacific Blood Plasma Fractionators, by Country USD Million (2021-2026)
  • Table 151. Asia Pacific Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 152. Asia Pacific Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 153. Asia Pacific Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 154. China Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 155. China Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 156. China Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 157. Japan Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 158. Japan Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 159. Japan Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 160. India Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 161. India Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 162. India Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 163. South Korea Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 164. South Korea Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 165. South Korea Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 166. Singapore Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 167. Singapore Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 168. Singapore Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 169. Australia Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 170. Australia Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 171. Australia Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 172. Rest of Asia-Pacific Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 173. Rest of Asia-Pacific Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 174. Rest of Asia-Pacific Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 175. Europe Blood Plasma Fractionators, by Country USD Million (2021-2026)
  • Table 176. Europe Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 177. Europe Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 178. Europe Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 179. Germany Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 180. Germany Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 181. Germany Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 182. France Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 183. France Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 184. France Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 185. Italy Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 186. Italy Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 187. Italy Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 188. United Kingdom Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 189. United Kingdom Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 190. United Kingdom Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 191. Netherlands Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 192. Netherlands Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 193. Netherlands Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 194. Spain Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 195. Spain Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 196. Spain Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 197. Rest of Europe Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 198. Rest of Europe Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 199. Rest of Europe Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 200. MEA Blood Plasma Fractionators, by Country USD Million (2021-2026)
  • Table 201. MEA Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 202. MEA Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 203. MEA Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 204. Saudi Arabia Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 205. Saudi Arabia Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 206. Saudi Arabia Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 207. Turkey Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 208. Turkey Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 209. Turkey Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 210. Israel Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 211. Israel Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 212. Israel Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 213. United Arab Emirates Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 214. United Arab Emirates Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 215. United Arab Emirates Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 216. South Africa Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 217. South Africa Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 218. South Africa Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 219. Rest of Africa Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 220. Rest of Africa Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 221. Rest of Africa Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 222. North America Blood Plasma Fractionators, by Country USD Million (2021-2026)
  • Table 223. North America Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 224. North America Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 225. North America Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 226. United States Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 227. United States Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 228. United States Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 229. Canada Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 230. Canada Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 231. Canada Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 232. Mexico Blood Plasma Fractionators, by Type USD Million (2021-2026)
  • Table 233. Mexico Blood Plasma Fractionators, by Application USD Million (2021-2026)
  • Table 234. Mexico Blood Plasma Fractionators, by End-User USD Million (2021-2026)
  • Table 235. Research Programs/Design for This Report
  • Table 236. Key Data Information from Secondary Sources
  • Table 237. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Blood Plasma Fractionators: by Type USD Million (2015-2020)
  • Figure 5. Global Blood Plasma Fractionators: by Application USD Million (2015-2020)
  • Figure 6. Global Blood Plasma Fractionators: by End-User USD Million (2015-2020)
  • Figure 7. South America Blood Plasma Fractionators Share (%), by Country
  • Figure 8. Asia Pacific Blood Plasma Fractionators Share (%), by Country
  • Figure 9. Europe Blood Plasma Fractionators Share (%), by Country
  • Figure 10. MEA Blood Plasma Fractionators Share (%), by Country
  • Figure 11. North America Blood Plasma Fractionators Share (%), by Country
  • Figure 12. Global Blood Plasma Fractionators share by Players 2020 (%)
  • Figure 13. Global Blood Plasma Fractionators share by Players (Top 3) 2020(%)
  • Figure 14. Global Blood Plasma Fractionators share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. CSL (Australia) Revenue, Net Income and Gross profit
  • Figure 17. CSL (Australia) Revenue: by Geography 2020
  • Figure 18. Grifols (Spain) Revenue, Net Income and Gross profit
  • Figure 19. Grifols (Spain) Revenue: by Geography 2020
  • Figure 20. Shire (Ireland) Revenue, Net Income and Gross profit
  • Figure 21. Shire (Ireland) Revenue: by Geography 2020
  • Figure 22. Octapharma (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Octapharma (Switzerland) Revenue: by Geography 2020
  • Figure 24. Kedrion (Italy) Revenue, Net Income and Gross profit
  • Figure 25. Kedrion (Italy) Revenue: by Geography 2020
  • Figure 26. LFB (France) Revenue, Net Income and Gross profit
  • Figure 27. LFB (France) Revenue: by Geography 2020
  • Figure 28. Biotest (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Biotest (Germany) Revenue: by Geography 2020
  • Figure 30. Takeda Pharmaceutical Company (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Takeda Pharmaceutical Company (Japan) Revenue: by Geography 2020
  • Figure 32. Bio Products Laboratory (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. Bio Products Laboratory (United Kingdom) Revenue: by Geography 2020
  • Figure 34. Bharat Serums and Vaccines Limited (India) Revenue, Net Income and Gross profit
  • Figure 35. Bharat Serums and Vaccines Limited (India) Revenue: by Geography 2020
  • Figure 36. Global Blood Plasma Fractionators: by Type USD Million (2021-2026)
  • Figure 37. Global Blood Plasma Fractionators: by Application USD Million (2021-2026)
  • Figure 38. Global Blood Plasma Fractionators: by End-User USD Million (2021-2026)
  • Figure 39. South America Blood Plasma Fractionators Share (%), by Country
  • Figure 40. Asia Pacific Blood Plasma Fractionators Share (%), by Country
  • Figure 41. Europe Blood Plasma Fractionators Share (%), by Country
  • Figure 42. MEA Blood Plasma Fractionators Share (%), by Country
  • Figure 43. North America Blood Plasma Fractionators Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • CSL (Australia)
  • Grifols (Spain)
  • Shire (Ireland)
  • Octapharma (Switzerland)
  • Kedrion (Italy)
  • LFB (France)
  • Biotest (Germany)
  • Takeda Pharmaceutical Company (Japan)
  • Bio Products Laboratory (United Kingdom)
  • Bharat Serums and Vaccines Limited (India)
Additional players considered in the study are as follows:
Shanghai RAAS Blood Products (China) , Sichuan YuandaShuyang Pharmaceutical Co., Ltd. (China) , KabaFusion (United States) , Centurion Pharma (Turkey)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation